RBC Capital Maintains Outperform on CVS Health, Raises Price Target to $107

Benzinga Newsdesk www.benzinga.com Positive 88.2%

Neg 0% Neu 0% Pos 88.2%

RBC Capital analyst Ben Hendrix maintains CVS Health (NYSE:CVS) with a Outperform and raises the price target from $93 to $107.